ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

ClinicalTrials.gov ID: NCT05295732

Public ClinicalTrials.gov record NCT05295732. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The ASCEND Study: A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 - With a Parallel Optional Maximal Use Arm - in the Treatment of RXLI (X-linked) or ARCI Ichthyosis in Subjects Aged ≥6 Years

Study identification

NCT ID
NCT05295732
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Timber Pharmaceuticals Inc.
Industry
Enrollment
153 participants

Conditions and interventions

Conditions

Interventions

  • Matching Vehicle Drug
  • TMB-001 Drug

Drug

Eligibility (public fields only)

Age range
6 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 20, 2022
Primary completion
Jun 16, 2024
Completion
Sep 22, 2024
Last update posted
Mar 19, 2026

2022 – 2024

United States locations

U.S. sites
18
U.S. states
16
U.S. cities
18
Facility City State ZIP Site status
U.S. Dermatology Partners Phoenix Arizona 85006
Stanford University School of Medicine Palo Alto California 94304
About Skin Dermatology Centennial Colorado 80111
Yale Center for Clinical Investigation New Haven Connecticut 06519
Department of Dermatology and Cutaneous Surgery, University of Miami Miami Florida 33136
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois 60611
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana 46250
The Indiana Clinical Trials Center Plainfield Indiana 46168
Associated Skincare Specialists New Brighton Minnesota 55112
University of Mississippi Medical Center (UMMC) Jackson Mississippi 39216
Wake Forest University Health Sciences Winston-Salem North Carolina 27104
Optima Research Boardman Ohio 44512
Children's Hospital of Philadelphia (CHOP) Philadelphia Pennsylvania 19104
Medical University of South Carolina Charleston South Carolina 29425
Austin Institute for Clinical Research Houston Texas 77056
Austin Institute for Clinical Research, Inc. Pflugerville Texas 78660
Virginia Clinical Research-Pariser Dermatology Specialists Norfolk Virginia 23502
North Sound Dermatology Mill Creek Washington 98012

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05295732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 19, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05295732 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →